Dr. Xuekui Liu is currently the Deputy Director of the Department of Head and Neck Surgery at the Sun Yat-sen University Cancer Center, serving as a Chief Physician, Doctoral Supervisor, and Principal Investigator (PI) in clinical research on head and neck tumors. Dr. Liu specializes in the diagnosis, surgical treatment, and comprehensive management of head and neck tumors, including thyroid cancer, tongue cancer, hypopharyngeal cancer, and laryngeal cancer. He is particularly skilled in the reconstruction and repair of defects following head and neck tumor surgeries.

Surgical treatments for laryngeal cancer that preserve laryngeal function.

2009.06–2009.08: Fellowship, University of Alberta Hospital, Canada, Department of Head and Neck Surgery

2007.09–2007.12: Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University, Department of Oral and Maxillofacial Surgery

2001.09–2004.06: Sun Yat-sen University – Ph.D. in Oncology

1994.09–1997.06: Jiangxi Medical College – Master’s Degree in Medicine

1986.07–1991.06: Jiangxi Medical College – Bachelor’s Degree in Medicine

1. Wu D, Li Y, Xu P, Fang Q, Cao F, Lin H, Li Y, Su Y, Lu L, Chen L, Li Y, Zhao Z, Hong X, Li G, Tian Y, Sun J, Yan H, Fan Y, Zhang X, Li Z, Liu X. Neoadjuvant chemo-immunotherapy with camrelizumab plus nab-paclitaxel and cisplatin in resectable locally advanced squamous cell carcinoma of the head and neck: a pilot phase II trial. Nat Commun. 2024 Mar 11;15(1):2177. doi: 10.1038/s41467-024-46444-z

2. Lin P, Xie W, Li Y, Zhang C, Wu H, Wan H, Gao M, Liang F, Han P, Chen R, Cheng G, Liu X, Fan S, Huang X. Intratumoral and peritumoral radiomics of MRIs predicts pathologic complete response to neoadjuvant chemoimmunotherapy in patients with head and neck squamous cell carcinoma. J Immunother Cancer. 2024 Nov 5;12(11):e009616. doi: 10.1136/jitc-2024-009616

3. Zhao Z, Huang Y, Wang J, Lin H, Cao F, Li S, Li Y, Li Z, Liu X. A self-assembling CXCR4-targeted pyroptosis nanotoxin for melanoma therapy. Biomater Sci. 2023 Mar 14;11(6):2200-2210. doi: 10.1039/d2bm02026b

4. Wang N, Yan H, Wu D, Zhao Z, Chen X, Long Q, Zhang C, Wang X, Deng W, Liu X. PRMT5/Wnt4 axis promotes lymph-node metastasis and proliferation of laryngeal carcinoma. Cell Death Dis. 2020 Oct 15;11(10):864. doi: 10.1038/s41419-020-03064-x

5. Xu P, Fang Q, Zhao Z, Cao F, Wu D, Liu X. Evaluation of neoadjuvant chemotherapy combined with PD-1 inhibitors in patients with oropharyngeal and hypopharyngeal squamous cell carcinoma: a comparative study of antitumor activity. Cancer Immunol Immunother. 2023 Dec;72(12):4209-4219. doi: 10.1007/s00262-023-03557-6

6. Fang Q, Xu P, Cao F, Wu D, Liu X. PD-1 Inhibitors combined with paclitaxel (Albumin-bound) and cisplatin for larynx preservation in locally advanced laryngeal and hypopharyngeal squamous cell carcinoma: a retrospective study. Cancer Immunol Immunother. 2023 Dec;72(12):4161-4168. doi: 10.1007/s00262-023-03550-z

7. Peng J, Luo G, Yu Y, Ning K, Liu X. Retrospective assessment of neoadjuvant camrelizumab combined with induction chemotherapy: efficacy in laryngeal preservation for advanced hypopharyngeal and laryngeal squamous cell carcinoma. Cancer Immunol Immunother. 2024 Feb 15;73(3):54. doi: 10.1007/s00262-023-03579-0

8. Liu C, Liao L, Wu G, Yan H, Chen X, Wang C, Zheng X, Zeng Z, Zhao Z, Wu D, Liu X. Radiation-induced second primary squamous cell carcinoma of the oral cavity after radiotherapy for nasopharyngeal carcinoma. Oral Oncol. 2020 Jun 27;109:104863. doi: 10.1016/j.oraloncology.2020.104863

9. Wu D , Zhao Z , Wang N , Zhang X , Yan H , Chen X , Fan Y , Liu W , Liu X . Fluorescence imaging-guided multifunctional liposomes for tumor-specific phototherapy for laryngeal carcinoma. Biomater Sci. 2020 Jun 21;8(12):3443-3453. doi: 10.1039/d0bm00249f

10. Wu D, Fan Y, Yan H, Li D, Zhao Z, Chen X, Yang X, Liu X. “Oxidation-sensitive polymeric nanocarrier-mediated cascade PDT chemotherapy for synergistic cancer therapy and potentiated checkpoint blockade immunotherapy.” Chemical Engineering Journal 404 (2021): 126481.